- Home
- SUNS vs MCRB Comparison
SUNS vs MCRB Comparison
Compare SUNS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNS
- MCRB
- Stock Information
- Founded
- SUNS 2023
- MCRB 2010
- Country
- SUNS United States
- MCRB United States
- Employees
- SUNS N/A
- MCRB N/A
- Industry
- SUNS Real Estate Investment Trusts
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SUNS Real Estate
- MCRB Health Care
- Exchange
- SUNS Nasdaq
- MCRB Nasdaq
- Market Cap
- SUNS 148.0M
- MCRB 144.6M
- IPO Year
- SUNS N/A
- MCRB 2015
- Fundamental
- Price
- SUNS $9.94
- MCRB $19.64
- Analyst Decision
- SUNS Strong Buy
- MCRB Hold
- Analyst Count
- SUNS 3
- MCRB 4
- Target Price
- SUNS $13.58
- MCRB $14.33
- AVG Volume (30 Days)
- SUNS 73.0K
- MCRB 178.9K
- Earning Date
- SUNS 11-13-2025
- MCRB 11-12-2025
- Dividend Yield
- SUNS 12.06%
- MCRB N/A
- EPS Growth
- SUNS N/A
- MCRB N/A
- EPS
- SUNS 1.04
- MCRB 10.22
- Revenue
- SUNS $16,359,932.00
- MCRB N/A
- Revenue This Year
- SUNS $183.25
- MCRB N/A
- Revenue Next Year
- SUNS $62.46
- MCRB N/A
- P/E Ratio
- SUNS $9.54
- MCRB $1.92
- Revenue Growth
- SUNS 1342.10
- MCRB N/A
- 52 Week Low
- SUNS $7.80
- MCRB $6.53
- 52 Week High
- SUNS $15.74
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- SUNS 34.63
- MCRB 56.40
- Support Level
- SUNS $9.77
- MCRB $19.14
- Resistance Level
- SUNS $10.29
- MCRB $21.50
- Average True Range (ATR)
- SUNS 0.31
- MCRB 1.46
- MACD
- SUNS -0.14
- MCRB 0.13
- Stochastic Oscillator
- SUNS 6.20
- MCRB 69.59
About SUNS Sunrise Realty Trust Inc. Common Stock
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.